FIG. 14A



A1
(a)
uM Pi
nM hCD39(ECD)
buffer
A1
POM-1
OAW42 Cells
(b)
uM Pi
untreated
POM-1
ARL
25 ug/ml mIgG1
10 ug/ml mIgG1
25 ug/ml A1
10 ug/ml A1
(c)
27536
28347
27597
27571
27579
A1
nm
Time (sec)

FIG. 14B





(a)
27536
uM Pi
nM CD39
hIgG
27536
POM-1
28337
buffer
28337
POM-1
(b)
OAW42 Cells
MEL-28 Cells
uM Pi
untreated
POM-1
ARL
50 ug/ml hIgG
15 ug/ml hIgG
5 ug/ml hIgG1
50 ug/ml 27536
15ug/ml 27536
5 ug/ml 27536
50 ug/ml 28337
15 ug/ml 28337
5 ug/ml 28337
30 min mAb pre-Treatment
(c)
27579
A1
28347
27571
27536
28337
nm
Time (sec)

FIG. 14C

(a)


27549
uM Pi
nM CD39
hIgG
27549
POM-1
27549
uM Pi
uM ATP
buffer
27549
POM-1

(b)


MEL-28 Cells
uM Pi
untreated
ARL
50 ug/ml hIgG
15 ug/ml hIgG
5 ug/ml hIgG
1.5 ug/ml hIgG
0.5 ug/ml hIgG
50 ug/ml 27549
15 ug/ml 27549
5 ug/ml 27549
1.5 ug/ml 27549
0.5 ug/ml 27549
30 min mAb pre-Treatment
MEL-28 Cells
uM Pi
untreated
POM-1
ARL
15 ug/ml hIgG
5 ug/ml hIgG
1.5 ug/ml hIgG
0.5 ug/ml hIgG
15 ug/ml 27549
5 ug/ml 27549
1.5 ug/ml 27549
0.5 ug/ml 27549
18h mAb pre-treatement

(c)



27571
27536
A1
27549
nm
Time (s)

FIG. 14F




31895
31418
31873
31901
9-8B
BY40v9
A1
Chimera 2
Chimera 2/ A150D
Chimera 2/ S153E
Chimera 4
Anti-hCD39 antibody
Anti-mCD39 antibody

FIG. 14G


31895
31418
31901
9-8B
N99D
R154T
N99D/R154T
S153E/R154T
Anti-Fc-PE
Anti-mCD39-APC